{"id":"NCT02326272","sponsor":"UCB Biopharma S.P.R.L.","briefTitle":"A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-15","primaryCompletion":"2016-01-05","completion":"2018-09-12","firstPosted":"2014-12-29","resultsPosted":"2018-08-13","lastUpdate":"2019-10-03"},"enrollment":227,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis","Plaque Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia","CDP870","CZP"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"CZP 200 mg","type":"EXPERIMENTAL"},{"label":"CZP 400 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.","primaryOutcome":{"measure":"Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo Q2W (RS)","deltaMin":11.6,"sd":null},{"arm":"CZP 200 mg Q2W (RS)","deltaMin":81.4,"sd":null},{"arm":"CZP 400 mg Q2W (RS)","deltaMin":82.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":23,"countries":["United States","Austria","Canada","Poland"]},"refs":{"pmids":["29660421","36509889","32652544","32531798"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":170},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Psoriasis","Sinusitis"]}}